Positive effect of stereotactic body radiation therapy (SBRT) followed by sorafenib in patients with hepatocellular carcinoma

A new study provides evidence for the safety and efficacy of stereotactic body radiation therapy followed by sorafenib (SBRT/S) in improving OS, PFS, and QoL in patients with hepatocellular carcinoma. The study was presented at ASCO GI and in this medtalk by Laura Dawson, Professor and Chair of the Department of Radiation Oncology at the University of Toronto.